Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Abstral, accomplished, adjunct, Aerogen, aforementioned, aggravated, Alfred, Amaryl®and, Anderson, Argentina, Australasia, Australasian, Avandia®and, baseline, binding, binominal, blinatumomab, Brusegard, budget, Bull, Byetta®and, Calgary, Canam, Capsulin, categorization, celecoxib, chance, Chapel, charity, CIN, Cobalamin, Colonel, contemplated, counterclaim, Craig, dalteparin, Dance, database, decade, decided, defense, deficiency, DGCL, Diabetology, digital, dipeptidyl, discharge, discharged, discrimination, dismissal, dismissed, DME, donation, Eagle, economist, economy, editorial, EMA, equitable, explanatory, Faculty, father, fluctuate, foundation, fourteen, FRACP, FRCPA, Friedman, German, Glynase, Golden, graduate, graduated, harassment, heard, hematology, hope, ICOM, ideal, imposed, infliction, insolvency, internationally, internist, intraepithelial, IR, irinotecan, Januvia, Journal, keystone, Khazak, Leadership, leveraging, Lieutenant, lymphoblastic, mapping, Meda, MediPharma, mental, Montefiore, mortgage, neoplasia, NOL, notification, Onglyza, OnQ, orientation, OSLO, oversee, overseeing, PecFent, peptidase, Peru, pharmacokinetic, Phil, prejudiced, premature, Prince, promulgated, Prostrakan, quickly, ready, realigned, recurrent, relocated, Royal, Rxi, Ryerson, secondary, sensitivity, Shore, spatial, spend, spending, spin, spinout, sublicensing, sublingual, subscription, Sydney, taught, Tristar, Victoza, violation, Windsor, wrongly
Removed:
Abajian, Abbreviated, accountant, acquiree, acquirer, added, addressed, adecatumumab, advice, aggressively, AmerisourceBergen, anticipated, appeal, arithmetic, Armed, Armenian, Asia, assumed, auditing, Australian, baboom, bargain, bedtime, Bentley, brokering, caffeine, chairman, chromatography, claimed, colorectal, commitment, complementary, concentrate, Concurrence, consecutive, contingency, contracting, contractually, coupon, covenant, CPG, deadline, deal, description, diagnostic, dieting, disagreement, disclaimer, divided, dossier, Electro, EMEA, Eva, extension, FACP, factor, Fairfield, fatigue, Finally, flavored, formation, formula, forthcoming, founded, frequent, Frisch, GAAP, Georgia, ginseng, goodwill, house, implemented, indeterminate, instant, instrumentation, invented, Jersey, Kazakhstan, Kerr, Kohl, length, Lincoln, Lovaxin, mainstream, Manager, marketplace, media, merit, metastatic, Millipore, monitoring, Montefore, month, Nastech, neighboring, nonconvertible, nonforfeitable, nongovernmental, Nordic, notify, observe, online, OPEC, opened, opening, opioid, optimize, Panel, Park, partial, Paterson, pension, played, pre, prosecute, pursued, reaching, Red, regional, repaid, requested, routine, running, serving, solicit, spun, St, stating, successor, supplemented, territorial, Teva, threefold, tolerant, travel, trustee, twenty, UniPharm, upper, veterinarian, Village, VWAP, warranty, week, wholesale, wrote
Filing tables
Filing exhibits
GNBTQ similar filings
Filing view
External links
Exhibit 32
CERTIFICATIONS
Pursuant to Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. ss. 1350, as adopted), Mark A. Fletcher, Chief Executive Officer and President of Generex Biotechnology Corporation (the "Company"), and Stephen Fellows, Acting Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
1. The Company's Annual Report on Form 10-K for the period ended July 31, 2011 to which this Certification is attached as Exhibit 32 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of the period covered by the Report.
| DATE: October 14, 2011 | By: /s/ Mark A. Fletcher |
| Mark A. Fletcher | |
| Chief Executive Officer & President | |
| (Principal Executive Officer) |
| DATE: October 14, 2011 | By: /s/ Stephen Fellows |
| Stephen Fellows | |
| Acting Chief Financial Officer | |
| (Principal Financial and Accounting Officer) |